Long-term Infliximab Maintenance Therapy for Ulcerative Colitis
The ACT-1 and ACT-2 Extension Studies

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze a Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze
Published in: Gastroent Hepatol 2012; 66(4): 286-288
Category: Commentary

Sources

1. Reinisch W, Sandborn WJ, Rutgeerts P et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18(2): 201–211.

2. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462–2476.

3. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137(4): 1250–1260.

4. Reinisch W. Biologic therapy of ulcerative colitis: Infliximab, Adalimumab, Golimumab. In: Crohn’s disease and ulcerative colitis: from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. New York: Springer Science+Business Media LLC 2012.

5. Feagan BG, Reinisch W, Rutgeerts P et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102(4): 794–802.

6. Pannacione R, Ghosh S, Middleton S et al. Infliximab, Azathioprine, or Infliximab + Azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. Gastroenterology 2011; 140 (Suppl 1): S134.

7. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58(4): 501–508.

8. Travis SP, Stange EF, Lémann M et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2(1): 24–62.